A randomized, double-blind, placebo-controlled trial by Corpas et al
The manufacturers of these drugs have priced them at more than $1,000 per month, and limited competition in the space is putting them out of reach for many patients and creating financial burden on healthcare systems
Though not approved for therapeutic use, AOD 9604 remains an active product in scientific research for its role in metabolic regulation, joint health, and fat reduction
Weight loss medications have existed for a while, but they tended to be associated with limited weight loss results and problematic side effects, which did not allow for a wide-spread adoption by the masses
But Choquequirao offers a sense of discovery that Machu Picchu no longer has